DBVT
DBV Technologies S.A.
NASDAQ · Healthcare · Biotechnology · FR
$13.47
−1.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 15.7M | 4.8M |
| Cost of Revenue | 4.3M | — | 6.8M | — | — |
| Gross Profit | (4.3M) | — | (6.8M) | 15.7M | 4.8M |
| Operating Expenses | |||||
| R&D Expense | 124.3M | 116.7M | 89.9M | 60.2M | 75.5M |
| SG&A Expense | 50.6M | 36.0M | 23.8M | 31.9M | 25.9M |
| General & Admin Expense | 45.2M | 32.8M | 23.8M | 29.5M | 24.3M |
| Selling & Marketing Expense | 5.5M | 3.2M | — | 2.4M | 1.6M |
| Other Expenses | 1.9M | (5.6M) | — | (1.0K) | — |
| Total Operating Expenses | 176.9M | 147.1M | 113.7M | 92.2M | 101.5M |
| Cost and Expenses | 181.1M | 147.1M | 120.5M | 92.2M | 101.5M |
| Operating Income (EBIT) | (181.1M) | (147.1M) | (120.5M) | (76.4M) | (96.6M) |
| Non-Operating | |||||
| Interest Income | 2.6M | 601.0K | 2.7M | 3.7M | 427.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 2.6M | 601.0K | 2.7M | 3.7M | 427.0K |
| Other Non-Op Income/Expense | 2.2M | 600.0K | 2.7M | 3.7M | 427.0K |
| Non-Operating Income (excl Interest) | (1.1M) | (1.0K) | (2.7M) | 1.0K | — |
| EBT (Pre-Tax Income) | (178.9M) | (146.5M) | (117.8M) | (72.7M) | (96.2M) |
| Income Tax Expense | (3.1M) | 491.0K | (4.1M) | 7.0K | 70.0K |
| Bottom Line | |||||
| Net Income | (175.8M) | (146.9M) | (113.7M) | (72.7M) | (96.3M) |
| Earnings from Cont. Ops | (175.8M) | (146.9M) | (113.7M) | (72.7M) | (96.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (175.8M) | (146.9M) | (113.7M) | (72.7M) | (96.3M) |
| Per Share | |||||
| Basic EPS | ($1.98) | ($1.70) | ($1.20) | ($0.75) | ($1.25) |
| Diluted EPS | ($1.98) | ($1.70) | ($1.20) | ($0.75) | ($1.25) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.17 | $0.06 |
| Shares | |||||
| Basic Shares Outstanding | 85.7M | 86.4M | 96.2M | 95.1M | 77.4M |
| Diluted Shares Outstanding | 85.7M | 86.4M | 96.2M | 95.1M | 77.4M |
| Profitability Metrics | |||||
| EBITDA | (172.3M) | (139.3M) | (111.0M) | (63.3M) | (83.5M) |
| D&A | 7.7M | 7.7M | 6.8M | 13.2M | 13.2M |
| EBIT | (180.0M) | (147.1M) | (117.8M) | (76.4M) | (96.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026